March 2002

Treatment Considerations While Awaiting the Ideal Bullous Pemphigoid Trial

Author Affiliations

Not Available


Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Dermatol. 2002;138(3):404. doi:10.1001/archderm.138.3.404

THE SEARCH for an effective and safe therapy for bullous pemphigoid (BP) is important. Compared with other cutaneous disorders, BP has a relatively high morbidity and may occasionally be fatal. It most frequently affects the elderly, who are especially susceptible to the adverse effects of systemic drugs such as corticosteroids. The first-line agents that are used by most dermatologists are systemic corticosteroids. In mild cases of BP, there is a tendency to use potent topical steroids or anti-inflammatory agents other than corticosteroids, such as oral antibiotics, nicotinamide, or dapsone. In rare instances, nonsteroidal immunosuppressive therapy is instituted.

First Page Preview View Large
First page PDF preview
First page PDF preview